Literature DB >> 6528883

Identification of antigenic components recognized by "membrane-bound" antibodies from ovarian cancer patients.

D D Taylor, H D Homesley, G J Doellgast.   

Abstract

Immunoglobulins, eluted from ascites fluid-derived membrane fragments, were used to identify antigens with which they react from ovarian cancer patients. These immunoglobulin preparations were demonstrated to bind antigens from ovarian tumors, but not from normal ovaries. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was used to identify the components responsible for the reactivity. The different patients' immunoglobulin preparations were reactive with a similar group of antigens; however, the level of response to each individual component varies. In previous studies, the acid-eluted immunoglobulin was shown to be reactive with tissues other than ovarian tumors. Relating this cross-reactivity with the antigens found in ovarian tumors, we found that some components were found only in ovarian tumors, and others appear to be shared by gynecologic tumors, in general. Of these antigens, most are apparently placental antigens. Two proteins were found in normal ovaries.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6528883     DOI: 10.1111/j.1600-0897.1984.tb00134.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 0271-7352            Impact factor:   3.886


  3 in total

1.  Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.

Authors:  Douglas D Taylor; Cicek Gercel-Taylor; Lynn P Parker
Journal:  Gynecol Oncol       Date:  2009-07-31       Impact factor: 5.482

Review 2.  Humoral innate immune response and disease.

Authors:  Stephanie N Shishido; Sriram Varahan; Kai Yuan; Xiangdong Li; Sherry D Fleming
Journal:  Clin Immunol       Date:  2012-06-18       Impact factor: 3.969

3.  Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects.

Authors:  D D Taylor; C Gerçel-Taylor
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.